Good to see you back posting again, you were missed.

Prior to December 2008 the minimum listing price was $5 but this has now been brought down to $4.

http://www.sec.gov/rules/sro/nasdaq/2008/34-59087.pdf

As to extending a patent, there are specific reasons under which this can be done, for example, regulatory review by the FDA and, basically, the time under stautory review is added to the end of the patent duration. I can see no such grounds with the MMP Portfolio.

However, any company put on notice can still be prosecuted after expiry of a patent.

Further to DT, I believe that their actions were based on possible infringement of the broader German patent, which I belive is stronger than the individual MMP Portfolio US patents. In the event that one German company licenses I wonder how long it would be before others follow?

.

.

Be well